RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Adamis Pharmaceuticals Stock

Adamis Pharmaceuticals P/S 2024

Adamis Pharmaceuticals P/S

0.03

Ticker

ADMP

ISIN

US00547W2089

WKN

A1XA2F

As of Oct 10, 2024, Adamis Pharmaceuticals's P/S ratio stood at 0.03, a -88.46% change from the 0.26 P/S ratio recorded in the previous year.

The Adamis Pharmaceuticals P/S history

Adamis Pharmaceuticals Aktienanalyse

What does Adamis Pharmaceuticals do?

Adamis Pharmaceuticals Corp is a biotechnology company based in the USA that specializes in the development of pharmaceuticals and medical devices. The company was founded in 2006 and is headquartered in San Diego, California. History: Adamis Pharmaceuticals was founded by Dr. Dennis J. Carlo, an experienced pharmaceutical executive with over 35 years of industry experience. The company initially focused on the development of therapeutics for the treatment of allergies and respiratory diseases. Over the years, the company has expanded its portfolio and specialized in the development of drugs for the treatment of anaphylaxis, asthma, and prostate cancer, as well as medical devices for drug delivery. Business model: Adamis Pharmaceuticals focuses on the development of novel drugs and medical devices that can improve patients' lives. The company seeks opportunities to meet unmet medical needs in existing therapy areas. Adamis collaborates closely with leading medical institutions and research facilities to develop and market a portfolio of innovative products. Various divisions: The company has various divisions, including: 1. Allergy/Respiratory: Adamis Pharmaceuticals has developed a broad portfolio of therapeutic agents for the treatment of allergies and respiratory diseases. The company has also developed a patented device called Symjepi, which is used to treat anaphylaxis, a life-threatening allergic reaction. This device also allows untrained individuals to self-treat in an anaphylaxis situation. 2. Oncology: Adamis Pharmaceuticals has developed a novel drug called TeloBlast®, which is used to treat prostate cancer. TeloBlast® targets telomerase, which is upregulated in many types of cancer. The company intends to develop additional drugs for the treatment of cancer in the future. 3. CNS: Adamis Pharmaceuticals has also developed innovative drugs for the treatment of CNS (central nervous system) disorders. The company plans to bring several new drugs for the treatment of neurological disorders to the market by 2022. 4. Medical devices: Adamis Pharmaceuticals has developed a range of patented medical devices, including the ZIM high-pressure injection pump, which allows doctors and nurses to administer medications quickly and accurately. Products: Adamis Pharmaceuticals' products include: 1. Symjepi: A patented device for the treatment of anaphylaxis. 2. TeloBlast®: A novel drug for the treatment of prostate cancer. 3. ZIM high-pressure injection pump: A patented medical device for drug administration. 4. Fluticasone/Salmeterol: An inhalable combination drug for the treatment of asthma and COPD (chronic obstructive pulmonary disease). Adamis Pharmaceuticals is an innovative biotechnology company specializing in the development of pharmaceuticals and medical devices. The company aims to meet unmet medical needs and improve patients' lives. With a broad portfolio of products and a strong commitment to research and development, Adamis Pharmaceuticals is well positioned to continue growing in the future. Adamis Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Adamis Pharmaceuticals's P/S Ratio

Adamis Pharmaceuticals's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Adamis Pharmaceuticals's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Adamis Pharmaceuticals's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Adamis Pharmaceuticals’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Adamis Pharmaceuticals stock

What is the price-to-earnings ratio of Adamis Pharmaceuticals?

The price-earnings ratio of Adamis Pharmaceuticals is currently 0.03.

How has the price-earnings ratio of Adamis Pharmaceuticals changed compared to last year?

The price-to-earnings ratio of Adamis Pharmaceuticals has increased by -88.46% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Adamis Pharmaceuticals high compared to other companies?

Yes, the price-to-earnings ratio of Adamis Pharmaceuticals is high compared to other companies.

How does an increase in the price-earnings ratio of Adamis Pharmaceuticals affect the company?

An increase in the price-earnings ratio of Adamis Pharmaceuticals would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Adamis Pharmaceuticals affect the company?

A decrease in the price-earnings ratio of Adamis Pharmaceuticals would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Adamis Pharmaceuticals?

Some factors that influence the price-earnings ratio of Adamis Pharmaceuticals are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Adamis Pharmaceuticals pay?

Over the past 12 months, Adamis Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Adamis Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Adamis Pharmaceuticals?

The current dividend yield of Adamis Pharmaceuticals is .

When does Adamis Pharmaceuticals pay dividends?

Adamis Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Adamis Pharmaceuticals?

Adamis Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Adamis Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Adamis Pharmaceuticals located?

Adamis Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Adamis Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Adamis Pharmaceuticals from 10/10/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/10/2024.

When did Adamis Pharmaceuticals pay the last dividend?

The last dividend was paid out on 10/10/2024.

What was the dividend of Adamis Pharmaceuticals in the year 2023?

In the year 2023, Adamis Pharmaceuticals distributed 0 USD as dividends.

In which currency does Adamis Pharmaceuticals pay out the dividend?

The dividends of Adamis Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Adamis Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Adamis Pharmaceuticals

Our stock analysis for Adamis Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Adamis Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.